Clinical trials: Hypertension, Pulmonary Arterial
Pulmonary Arterial Hypertension, Heart Defects, Congenital
The Effects of the Otago Exercise Program
The objective of this experimental study is to conduct a comparative evaluation of the effects of a supervised Otago Exercise Program (OEP) functional exercise capacity, blood lactate levels, dyspnea, fatigue, peripheral muscle…
- Trial name
- NCT06172790
- Testing
- Training
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Istanbul University - Cerrahpasa
Pre-Pulmonary Atrial Hypertension
Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension
This research study is looking at the use of the drug ambrisentan and if it can improve right ventricle function in people with systemic sclerosis-associated pre-pulmonary arterial hypertension.
- Trial name
- AMERICA-PAH (NCT02169752)
- Testing
- Ambrisentan
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Jewish Health
Pulmonary Arterial Hypertension
Myocardial Metabolic Flux in Pulmonary Arterial Hypertension
The rationale for this study is that GLP-1 agonist treatment is likely to influence myocardial substrate utilisation, changing the predominant source of metabolic energy within the heart to a more energetically efficient form.
- Trial name
- NCT07737522
- Testing
- GLP-1 agonist
- Volunteers
- 32 people
- Sponsor
- Imperial College London
High Altitude Effects, High Altitude
Assessment of Heart Rate Variability HRV During Descent DE From 2850m to Sea Level and During Re-ascent A From Sea Level to 2850m in Patients With Pulmonary Arterial Hypertension PAH
To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level and re-ascent from sea level to 2850m on heart rate variability and other hemodynamic parameters in patients with pulmonary arterial…
- Conditions
- High Altitude Effects, High Altitude, Pulmonary Vascular Disease, Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT07801859
- Testing
- Descent and re-ascent (2850m, sea level)
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Hypertension
Neuromodulation in Patients With Pulmonary Arterial Hypertension
Patients with Group 1 pulmonary hypertension will be enrolled in this study. Investigators will test the hypothesis of low-level tragal stimulation in patients with pulmonary hypertension.
- Trial name
- NIP (NCT06802380)
- Testing
- Low-level tragus stimulation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Oklahoma
Pulmonary Arterial Hypertension
BEET PAH: a Study to Assess the Effects of Beetroot Juice in Patients With Pulmonary Arterial Hypertension
The study is a single center randomised, double-blind, placebo-controlled crossover study to assess the effects of beetroot juice in patients with pulmonary arterial hypertension.
- Trial name
- BEET-PAH (NCT02000856)
- Testing
- Beetroot juice
- Where
- Sweden
- Volunteers
- 15 people
- Sponsor
- Uppsala University
Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Knowledge Translation Program for the guidelines and evidence-based management of PAH patients
- Trial name
- PAH QuERI Ext (NCT01389206)
- Testing
- observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
- Where
- 76 sites in United States, Puerto Rico
- Volunteers
- 797 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Treprostinil Combined With Tadalafil for Pulmonary Hypertension
Objectives: To test whether the combined administration of the medications treprostinil(a prostacycline therapy), and tadalafil(a PDE-5 [ phosphodiesterase type 5]Inhibitor therapy) is better than the administration of…
- Trial name
- T2 (NCT01302444)
- Testing
- Tadalafil
- Where
- 9 sites in United States
- Volunteers
- 1 people
- Sponsor
- Rhode Island Hospital
Pulmonary Hypertension
Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension
AMB-220-E is an international, multicenter, open-label study examining the long-term safety of ambrisentan (BSF 208075) in subjects who have previously completed Myogen study NCT00046319, "A Phase II, Randomized, Double-Blind…
- Trial name
- NCT00424021
- Testing
- ambrisentan
- Volunteers
- 54 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension
Effects of Physical Training on Vascular Function as a Therapeutic Target in Pulmonary Hypertension
The role of physical training in the treatment of pulmonary arterial hypertension (PAH) is controversial. The aim of the project is to evaluate the effect of physical training on markers of endothelial function and integrity and…
- Trial name
- NCT03550729
- Testing
- Endurance training
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Hospital Clinic of Barcelona
Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease
Assessment of Six-minute Walking Distance Between Sea Level LA vs. High Altitude HA After Re-ascent in Patients With Pulmonary Arterial Hypertension PAH
To study the effect of a re-ascent after a one-week stay at sea level (after prior descent from 2850m) to high altitude (Quito Ecuador: 2850m) on six-minute walking distance and other scores in patients with pulmonary arterial…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease, Six-minute Walk Test, NYHA
- Trial name
- NCT07797166
- Testing
- Re-Ascent sea level to 2850m
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Dapagliflozin in Pulmonary Arterial Hypertension
The purpose of this study is to investigate the effects of dapagliflozin on exercise capacity and hemodynamics in patients with pulmonary arterial hypertension
- Trial name
- DAPAH (NCT05179356)
- Testing
- Dapagliflozin 10 MG [Farxiga]
- Where
- Denmark
- Volunteers
- 52 people
- Sponsor
- Mads Ersbøll
Hypertension, Pulmonary, Hypertension;Pulmonary;Primary
Endtidal Carbon Dioxide for Earlier Detection of Pulmonary Hypertension
Measurement of the endtidal carbon dioxide by capnography to exclude or to ensure the diagnosis pulmonary hypertension. The aim of the study is to obtain an endtidal carbon dioxide cut-off value for the diagnostic algorithm for…
- Conditions
- Hypertension, Pulmonary, Hypertension;Pulmonary;Primary, Chronic Thromboembolic Pulmonary Hypertension, Vascular Diseases
- Trial name
- EARLIER (NCT03388476)
- Testing
- Capnography
- Where
- Germany
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Giessen
Intrahepatic Cholangiocarcinoma (Icc)
Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (ICC), the second most prevalent primary malignant liver neoplasm, features highly aggressive biological behavior and dismal prognosis.
- Trial name
- LPHAIC for ICC (NCT07646717)
- Testing
- hepatic arterial infusion chemotherapy (Irinotecan liposome plus 5-FU/LV) combined with lenvatinib and PD-1 inhibitors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pulmonary Arterial Hypertension
TReatment Of Pulmonary HYpertension 1-US Study
The objective of this study is to assess the safety, performance and initial effectiveness of the TIVUS™ System when used for pulmonary artery denervation through subjective and objective change in clinical parameters and…
- Trial name
- TROPHY 1-US (NCT02835950)
- Testing
- Therapeutic Intra-Vascular UltraSound (TIVUS™) System
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- SoniVie Inc.
Intrahepatic Cholangiocarcinoma (Icc)
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and…
- Trial name
- RAINBOW (NCT07691515)
- Testing
- Gemcitabine, Cisplatin, Tislelizumab
- Where
- 21 sites in China
- Volunteers
- 140 people
- Sponsor
- Zhejiang Cancer Hospital
Pulmonary Arterial Hypertension
Evaluation of the Role of Epstein-Bar Virus in Patients With Pulmonary Arterial Hypertension
Evaluate the role of Epstein-Barr virus infection in PAH (Idiopathic and connective tissue disease). This by obtaining a blood sample from the PAH patients undergoing right heart cathetrization as well as obtaining the…
- Trial name
- NCT06550648
- Testing
- Right Heart Catheterization (Swan Ganz Catheter)
- Where
- Egypt
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Cairo University
Pulmonary Arterial Hypertension With Congenital Cardiac Shunt
Evaluation of the Pulmonary Vascular Reactivity Test in Patients With Pulmonary Arterial Hypertension and a Cardiac Shunt
The purpose of this study is to assess the predictive performance of the pulmonary vascular reactivity to acetylcholine, in the presence pulmonary arterial hypertension (estimated 1 year after the closure of the shunt).
- Trial name
- ReVAch (NCT02138708)
- Testing
- Pharmacological test of pulmonary endothelial
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Arterial Hypertension, Diffuse Interstitial Lung Disease
HYPID (Pulmonary Hypertension in Interstitial Lung Disease) EXTENSION
HYPID-2 study is an extension of HYPID study (NCT01443598) : HYPID-2 is also an observational and prospective study of patients with interstitial lung disease and pre capillary hypertension diagnosed by right heart sided…
- Trial name
- HYPID-2 (NCT02799771)
- Where
- France
- Volunteers
- 210 people
- Sponsor
- Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
Pulmonary Arterial Hypertension
Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH
This is an observational, multicenter, single-day, Phase 2 study. This study will include a 14-day Screening Period and Study Day 1 clinic visit.
- Trial name
- PRN (NCT03888365)
- Testing
- Treprostinil, Non-Treprostinil PAH Medications
- Where
- 10 sites in United States
- Volunteers
- 43 people
- Sponsor
- United Therapeutics